TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Maraviroc Switch Collaborative Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Documented HIV-1 infection by a licensed diagnostic test at any time prior to study entry~* Age \>18 years~* HIV-1 RNA \<200 copies/mL plasma for at least 24 weeks~* Stable (\>24 weeks) ART including two N(t)RTIs and a PI/r~* No evidence of any primary HIV genotypic mutations in HIV reverse transcriptase or protease for all patients with available resistance testing results conducted prior to cART and/or during viral rebound/failure~* Provision of written, informed consent.~Exclusion Criteria:~* CXCR4 or CCR5/CXCR4 dual tropic HIV tropism or a non-reportable tropism result based on assessment using proviral DNA~* Anticipated need to modify current cART regimen for toxicity management in the next 6 months~* The following laboratory criteria,~  1. absolute neutrophil count (ANC) \<750 cells/µL~ 2. haemoglobin \<8.0 g/dL~ 3. platelet count \<50,000 cells/µL~ 4. serum AST, ALT \>5 x upper limit of normal (ULN)~* Active hepatitis B co-infection~* Pregnant women or nursing mothers~* Current use of any prohibited medications as described in product specific information.~* Hypersensitivity to soy or peanuts~* Acute therapy for serious infection or other serious medical illness (in the judgement of the site Principal Investigator) requiring systemic treatment and/or hospitalisation~* Use of immunomodulators (e.g. systemic corticosteroids, recombinant interleukin-2, interferon) within 30 days prior to screening~* Patients with current alcohol or illicit substance use that in the opinion of the site Principal Investigator would conflict with any aspect of the conduct of the study~* Patients unlikely to be able to remain in follow-up for the protocol-defined period~* Prisoners or subjects who are compulsorily detained (involuntary incarcerated).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No change (Type: NO_INTERVENTION): continue their current cART regimen
- Replace N(t)RTI drugs with Maraviroc (Type: ACTIVE_COMPARATOR): Replace N(t)RTI drugs with MVC at a dose of 150mg bid (MVC 300mg bid can be used at the discretion of the Investigator if the PI/r is fosamprenavir/r) and continue the PI/r
- Replace PI/r drugs with Maraviroc (Type: ACTIVE_COMPARATOR): Replace PI/r drugs with MVC at a dose of 300mg bid and continue 2N(t)RTI.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Increasing Naloxone Access for Persons Who Use Opioids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Current or past six months illicit use of opioids~* Electronic device access for online survey completion~* Willing to provide email address to receive survey link and compensation~* Able to read and speak English~* Willing to provide their contact information and that of two friends/family members~* Permanent address for mailing of naloxone kit~* Does not currently have a naloxone kit in possession~Exclusion Criteria:~* Contraindication for naloxone (known severe allergic reaction)~* Cognitive impairment or unstable psychiatric condition that interferes with the informed consent process

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Opioid Overdose Education and Naloxone Distribution (Type: EXPERIMENTAL): Participants will engage in online audiovisual training focused on recognizing the signs of an opioid overdose and the procedural steps for how to administer naloxone. Participants randomized to this arm will be provided with a naloxone nasal spray kit (4mg).
- Opioid Overdose Education (Type: ACTIVE_COMPARATOR): Participants will engage in online audiovisual training focused on recognizing the signs of an opioid overdose and the procedural steps for how to administer naloxone. Participants randomized to this arm will receive information about pharmacies in their area where they can purchase a naloxone kit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Childhood Social Phobia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of social phobia~Exclusion Criteria:~* Pervasive developmental disorders (PDD)~* Schizophrenia~* Major Depression~* IQ of less than 80~* Medical conditions contraindicating use of fluoxetine

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 16 Years
- Healthy Volunteers: t

Study Arms:
- Social Effectiveness Therapy for Children (Type: EXPERIMENTAL): Social Effectiveness Therapy for Children includes social skills training, peer generalization experiences and exposure therapy
- Fluoxetine (Type: EXPERIMENTAL): Fluoxetine given in 10mg doses, up to 40 mg as tolerated
- Pill placebo (Type: PLACEBO_COMPARATOR): Capsules identical to fluoxetine given in 10 mg. doses up to 40 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed,CLL/SLL, documented relapsed or refractory disease after at least one prior chemotherapy regimen.~* In cases of SLL, patients must have at least one bidimensionally measurable lesion at least ≥1.5 cm measured in one dimension.~* ECOG performance status of 0-2 at study entry~* Laboratory test results within these ranges: ANC \<=1500/μL, Platelet count \<= 100,000/μL. Patients with ANC \<1500/μL or plt \<100,000/μL with splenomegaly or extensive bone marrow involvement as the etiology for their cytopenias are eligible.~* creatinine clearance of \>60 mL/min as determined by the Cockcroft-Gault calculation.~* Total bilirubin \<= 2X upper limit laboratory normal (ULN). Patients with non-clinically significant elevations of bilirubin due to Gilbert's disease are not required to meet these criteria.~* Serum transaminases AST (SGOT) and ALT (SGPT) \<=5x ULN, Serum alkaline phosphatase ≤5 X ULN.~* Disease free of prior malignancies for ≥ 2 years with the exception of basal or squamous cell skin carcinoma, carcinoma in situ of the breast or cervix, or localized prostate cancer (treated definitively with hormone therapy, radiotherapy, or surgery).~* Patients may have received prior therapy with bendamustine or lenalidomide, but must not have disease that is refractory to bendamustine or lenalidomide.~* Prior therapy with rituximab is permitted, even in the setting of rituximab refractory disease.~Exclusion Criteria:~* Has received \>5 lines of prior therapy for their disease. Re-treatment with an identical regimen does not count as a new regimen.~* Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form or comply with the protocol treatment.~* Pregnant or breast feeding females. Lactating females must agree not to breast feed while taking lenalidomide.~* Prior history or current evidence of central nervous system or leptomeningeal involvement.~* Use of any other experimental drug or therapy within 28 days of baseline.~* Known hypersensitivity to thalidomide.~* The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.~* Known to be positive for HIV or infectious hepatitis, type B or C.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Induction/Maintenance chemotherapy (Type: EXPERIMENTAL): Bendamustine + rituximab induction therapy followed by lenalidomide maintenance therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Abdominal Binder in Colonoscopies Performed by Trainees

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female adults between the ages of 20-80~* Participants with ASA I-III (American Society of Anesthesiologists Class)~* Undergoing a colonoscopy at any of the study locations for:~I. CRC screening (first colonoscopy or 10 years follow up of negative exam). II. Surveillance (prior colonoscopy with polyps). III. Diagnostic colonoscopy performed to evaluate symptoms such as abdominal pain or rectal bleeding.~- Participants must have completed the full prescribed colonoscopy purgative preparation prior to their procedure and describe adequate cleansing.~Exclusion Criteria:~* Inability to provide informed consent.~* Patients with known or suspected pregnancy.~* Patients undergoing multiple procedures (e.g., upper and lower endoscopy).~* Previous colon resection surgery.~* History of problems with sedation or anesthesia.~* Patients with known or suspected diagnosis of inflammatory bowel disease (ulcerative colitis or Crohn's disease).~* Patients with a history of colorectal cancer or other intra-abdominal malignancy.~* Patients with open or recent wounds or skin rash on the anterior abdominal wall.~* History of cirrhosis or ascites.~* Patients who are medically unstable (American Society of Anesthesiology Class IV or above).

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Abdominal Binder Intervention Group (Type: EXPERIMENTAL): Patients randomized to the Abdominal Binder Intervention Group will have the abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt) secured firmly between the subcostal border and the anterior superior iliac spine area to the abdomen just prior the colonoscopy.
- Sham Group (Type: SHAM_COMPARATOR): Sham Group will have the abdominal binder (Revive 3-in-1 Postpartum Recovery Support Belt) secured firmly between the subcostal border and the anterior superior iliac spine area to the abdomen just prior the colonoscopy but it will be loosened just prior the procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Antidiabetic Metformin as a Novel Adjunct to Antidepressants in Major Depressive Disorder Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eighty adult outpatients with the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) diagnosis of MDD based on a MINI Neuropsychiatric Interview (MINI) (American Psychiatric Association., 2000; Sheehan et al., 1998), without psychotic features and a total 17 item HAM-D score of at least 18 with item 1 (depressed mood) scored 2 or greater were eligible (Hamilton, 1960).~* Patients were requested to be free of all the psychotropic and anti-inflammatory medications for at least 4 weeks before participating in the study.~Exclusion Criteria:~* Patients with bipolar I or bipolar II disorder~* Patients with personality disorders~* Patients with eating disorders~* Patients with substance dependence or abuse~* Patients with concurrent active medical condition~* Patients with history of seizures~* Patients with history of receiving Electroconvulsive therapy (ECT)~* Patients with diabetes and other inflammatory disorders~* Patients with allergy or contraindications to the used medications~* Patients with finally pregnant or lactating females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): Fluoxetine 20 mg capsule once daily for 12 week plus placebo tablet once daily for 12 weeks
- Metformin group (Type: EXPERIMENTAL): Fluoxetine 20 mg capsule once daily for 12 week plus Metformin 1000 mg XR tablet once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Mydriatic Drops in Premature Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Infants who were first ROP examinations~* infants born before 32 weeks.~Exclusion Criteria:~* Developmental ocular and/or systemic anomalies.~* Drug use that can affect vital values~* Unstable general condition~* Food intolerance~* Recurrent vomiting.

- Gender: ALL
- Minimum Age: 32 Weeks
- Maximum Age: 34 Weeks
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with COPD (GOLD stages II-IV) and matched healthy controls~* Caucasian or African American~* Both men and women~* Current and former smokers~Exclusion Criteria:~* GOLD Stage I~* Clinical diagnosis of heart disease, hypertension, or metabolic disease~* Vasoactive medications (i.e. nitrates, beta-blockers, ACE inhibitors, Viagra, etc.)~* Pulmonary hypertension~* Hypothyroidism~* Hyper-homocysteinemia~* Interstitial lung disease~* Phenylketonuria~* Pregnancy~* Sleep apnea~* Anemia~* Raynod's phenomenon~* Gangrene of the digits~* History of low platelets or coagulopathies~* Aspirin sensitivity or allergy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- COPD Patients (Type: EXPERIMENTAL): Patients with COPD~AOC protocol: Brachial artery flow-mediated dilation, direct assessment of oxidative stress via EPR spectroscopy (O2-) and biomarkers of oxidative stress (8-isoprostane, LH, SOD) will be assessed at baseline and 2 hours following ingestion of a single oral antioxidant cocktail (1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.) Antioxidant Cocktail: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid~BH4 protocol: Brachial artery flow-mediated dilation (FMD), markers of inflammation, and markers of oxidative stress will be assessed at baseline and following an increase in nitric oxide bioavailability after administering a single dose = 5 mg/kg of Tetrahydrobiopterin (BH4)
- Controls (Type: EXPERIMENTAL): Healthy age- and sex- matched controls~AOC protocol: Brachial artery flow-mediated dilation, direct assessment of oxidative stress via EPR spectroscopy (O2-) and biomarkers of oxidative stress (8-isoprostane, LH, SOD) will be assessed at baseline and 2 hours following ingestion of a single oral antioxidant cocktail (1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.) Antioxidant Cocktail: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid~BH4 protocol: Brachial artery flow-mediated dilation (FMD), markers of inflammation, and markers of oxidative stress will be assessed at baseline and following an increase in nitric oxide bioavailability after administering a single dose = 5 mg/kg of Tetrahydrobiopterin (BH4)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab to Treat Severe Hemophilia A

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Severe congenital hemophilia A~* Documented historical inhibitor titer to factor VIII of at least 5 BU/mL~* Inhibitor level greater than or equal to 5 BU/mL 5 to 14 days after initial factor VIII exposure during screening~Exclusion Criteria:~* Known hypersensitivities or allergies to murine and/or humanized antibodies~* Currently participating in investigational hemophilia studies~* HIV infected~* Any immunodeficiency disorder~* Liver disease and serum ALT or AST is greater than three times the upper limit of normal, albumin is less than 2.5g/dl, and/or INR is greater than 1.7~* Received interferon or other immunomodulatory drugs, such as steroids or cytotoxic therapy in the 30 days prior to study entry~* History of cardiac arrhythmias, any active febrile illness, kidney insufficiency, or pulmonary infiltrates~* Has previously received rituximab treatment~* Currently undergoing immune tolerance therapy~* Evidence of Hepatitis B (HBV) infection, defined as one of the following:~  * HBsAg positive~ * HBsAg negative, HBsAb negative, HBcAb positive, and HBV DNA positive~* Participants with a high responding inhibitor (at least 5 BU/mL) first detected fewer than 12 months prior to study entry, unless the participant has failed immune tolerance therapy, defined as one of the following:~  1. Failure to fulfill the criteria for full or partial success within 33 months, as defined by a factor VIII recovery greater than or equal to 66% of expected and half-life greater than or equal to 6 hours measured after a 72-hour treatment-free washout period~ 2. Failure to achieve greater than 20% reduction in inhibitor titer during each interim non-overlapping 6-month period of ITT in the absence of documented infection, with 9 months as the minimum treatment period and 33 months as the maximum possible duration of unsuccessful ITT~ 3. Withdrawal from ITT for any other reason~* Routinely receive factor VIII concentrate for the treatment of both major and minor bleeding events~* Has received factor VIII concentrate in the 7 days prior to study entry

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab (Type: EXPERIMENTAL): Rituximab administered at a dose of 375 mg/m2 by slow intravenous infusion once per week for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent prior to any study-mandated procedure;~* Male or female aged ≥ 18 years;~* Insomnia disorder according to DSM-5 criteria;~* Insomnia Severity Index score ≥ 15;~* Insufficient sleep quantity as collected subjectively in the sleep diary;~* Women of childbearing potential must have a negative and urine pregnancy test and use the contraception scheme up to at least 30 days after last study treatment intake.~Exclusion Criteria:~* Body mass index below 18.5 or above 40.0 kg/m2;~* Any lifetime history of of related breathing disorder, periodic limb movement disorder, restless legs syndrome, circadian rhythm disorder, rapid eye movement (REM) behavior disorder, narcolepsy, or apnea/ hypopnea;~* Cognitive behavioral therapy (CBT) only allowed if, the treatment started at least 1 month prior to Visit 3 and the subject agrees to continue this CBT throughout the study;~* Self-reported usual daytime napping ≥ 1 hour per day and ≥ 3 days per week;~* Acute or unstable psychiatric conditions diagnosed by the Mini International Neuropsychiatric Interview;~* Mini Mental State Examination (MMSE) score \< 25 in subjects ≥ 50 years;~* For female subjects: pregnant, lactating or planning to become pregnant during projected duration of the study;~* History or clinical evidence of any disease or medical condition or treatment, which may put the subject at risk of participation in the study or may interfere with the study assessments.~* Any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Daridorexant 25 mg (Type: EXPERIMENTAL): None
- Daridorexant 50 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Tranexamic Acid in Reducing Myomectomy Associated Blood Loss in Federal Teaching Hospital Abakaliki.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* non-pregnant women with symptomatic myomas women with no known contraindication to tranexamic acid~Exclusion Criteria:~* past history of thromboembolic disorder, ischaemic heart disease, malignancy or liver disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- group A: Cases that had tranexamic acid infusion (Type: EXPERIMENTAL): Group A had perioperative tranexamic acid infusion at the rate of 100mls per hour
- Group B: Control (Type: PLACEBO_COMPARATOR): control were given perioperative placebo at the rate of 100mls per hour

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete